- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07278336
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.
In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Recruiting
- Blacktown Hospital /ID# 282426
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Health - Monash Medical Centre - Clayton /ID# 281468
-
Melbourne, Victoria, Australia, 3000
- Recruiting
- Peter MacCallum Cancer Centre. /ID# 281751
-
-
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, France, 44805
- Recruiting
- Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
-
-
Rhone
-
Lyon, Rhone, France, 69373
- Recruiting
- Centre Leon Berard /ID# 280575
-
-
-
-
-
Haifa, Israel, 3109601
- Recruiting
- Rambam Health Care Campus /ID# 278418
-
Jerusalem, Israel, 91120
- Recruiting
- Hadassah Medical Center-Hebrew University /ID# 278420
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel, 5265601
- Recruiting
- The Chaim Sheba Medical Center /ID# 278416
-
-
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Recruiting
- National Cancer Center Hospital East /ID# 278604
-
-
Saitama
-
Hidaka, Saitama, Japan, 350-1298
- Recruiting
- Saitama Medical University International Medical Center /ID# 278437
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan, 411-8777
- Recruiting
- Shizuoka Cancer Center /ID# 278538
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Recruiting
- Unidade Local de Saude de Santa Maria /ID# 280296
-
Porto, Portugal, 4200-072
- Recruiting
- Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitari Vall d Hebron /ID# 280442
-
Madrid, Spain, 28040
- Recruiting
- Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
-
Madrid, Spain, 28050
- Recruiting
- Hospital Universitario HM Sanchinarro /ID# 280439
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Recruiting
- Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
-
-
-
-
-
Taipei, Taiwan, 112
- Recruiting
- Taipei Veterans General Hospital /ID# 281349
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital /ID# 280701
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope National Medical Center /ID# 281381
-
Irvine, California, United States, 92618
- Recruiting
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Sarah Cannon Research Institute at HealthONE /ID# 278785
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago Medical Center /ID# 278295
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Recruiting
- University Of Nebraska Medical Center /ID# 281020
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Recruiting
- NEXT Oncology - San Antonio /ID# 278606
-
-
Utah
-
West Valley City, Utah, United States, 84119
- Recruiting
- Start Mountain Region /ID# 278609
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Next Virginia /ID# 278607
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
- Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.
For Parts 1-4:
- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).
For Parts 5-6:
- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.
Exclusion Criteria:
- Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
- Participants with platinum refractory disease.
- Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
- Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
- Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.
For Parts 3-6:
- History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
- History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
- Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.
For Parts 5-6:
- Participants who had prior allergic reaction to platinum containing compound.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part 1: ABBV-901 Dose Escalation
Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Experimental: Part 2: ABBV-901 Optimization Dose A
Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Experimental: Part 2: ABBV-901 Optimization Dose B
Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Experimental: Part 2: ABBV-901 Optimization Dose C
Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Experimental: Part 3: ABBV-901 + Bevacizumab Escalation
Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) |
|
Experimental: Part 4: ABBV-901 + Bevacizumab Expansion
Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) |
|
Experimental: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation
Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) Intravenous (IV) |
|
Experimental: Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion
Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) Intravenous (IV) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with Adverse Events (AE)
Time Frame: Up to Approximately 3 Years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 3 Years
|
|
Overall Response (as assessed by the investigator)
Time Frame: Up to Approximately 3 Years
|
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator. |
Up to Approximately 3 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Response (as assessed by independent central review)
Time Frame: Up to Approximately 3 Years
|
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR). |
Up to Approximately 3 Years
|
|
Duration of Response (DOR)
Time Frame: Up to Approximately 3 Years
|
DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier. |
Up to Approximately 3 Years
|
|
Progression-free survival (PFS)
Time Frame: Up to Approximately 3 Years
|
PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
Time Frame: Up to Approximately 3 Years
|
OS is defined as time from first study treatment to death due to any cause. |
Up to Approximately 3 Years
|
|
Disease Control Rate
Time Frame: Up to Approximately 3 Years
|
Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria. |
Up to Approximately 3 Years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Ovarian Neoplasms
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Coordination Complexes
- Bevacizumab
- Carboplatin
Other Study ID Numbers
- M25-760
- 2025-522209-40-00 (Ctis)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.